Clinical trial
Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder
NCT00446719 · Mount Sinai Hospital, Canada, Other · Completed
Key facts
| NCT number | NCT00446719 |
|---|---|
| Title | Safety and Antidepressant Effects of Rellidep in Major Depressive Disorder |
| Official title | An Open-Label Pilot Study Evaluating the Safety and Antidepressant Effects of Rellidep (BI= Biological Isolate) in Major Depressive Disorder |
| Lead sponsor | Mount Sinai Hospital, Canada, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Depression |
| Intervention type | Drug |
| Interventions | Rellidep |
| Enrollment | 23 |
| Start date | Aug 1, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Mar 13, 2007 |
| Last update posted | Jan 5, 2011 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: